Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles (168)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00921934 |
Recruitment Status
:
Completed
First Posted
: June 17, 2009
Results First Posted
: October 26, 2012
Last Update Posted
: December 21, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Chronic viral infections induce oxidative stress that can cause a number of concomitant diseases, e.g. cardio-vascular diseases or metabolic disorders. Therefore, a sufficient treatment of oxidative stress may be of benefit for the patient to prevent further diseases.
Shingles (herpes zoster infection) have been successfully treated with antioxidative substances like high-dose vitamin C for ages. Not only the acute symptoms can be diminished by high-dose vitamin C. Even long-term sequelae, like painful post-herpetic neuropathy, may be mitigated or even fully avoided.
Condition or disease |
---|
Virus Diseases Herpes Zoster |
Study Type : | Observational |
Actual Enrollment : | 68 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | PASCORBIN 7.5g in the Treatment of Viral Infection, Especially Varicella Zoster Infection: An Observational Cohort Study |
Study Start Date : | April 2009 |
Actual Primary Completion Date : | December 2010 |
Actual Study Completion Date : | December 2010 |

Group/Cohort |
---|
Vitamin C
Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
|
- Change of Pain Measured by VAS [ Time Frame: visit 1 - 3 ]VAS (minimum = 0 = no pain, maximum = 10 = extrem pain, change of pain measured by VAS

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Due to the design of an Observational Cohort Study, no inclusion or exclusion criteria are named. The included patient group is described under "Cohort / Group".
Observational Criteria:
- adult patients
- acute viral infection (especially herpes zoster)
- Primary Care patient
- eligible for add-on therapy with vitamin C
- willingness to provide pseudonymized data to the Sponsor

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00921934
Germany | |
Praxis Dr. Schencking, Rheinstr. 77a | |
Ransbach-Baumbach, Rheinland-Pfalz, Germany, 56235 |
Principal Investigator: | Martin Schencking, MD | Rheinstr. 77a, D-56235 Ransbach-Baumbach | |
Study Director: | Bianka Krick | Pascoe Pharmazeutische Praeparate GmbH |
Responsible Party: | Pascoe Pharmazeutische Praeparate GmbH |
ClinicalTrials.gov Identifier: | NCT00921934 History of Changes |
Other Study ID Numbers: |
168 A 08 VC |
First Posted: | June 17, 2009 Key Record Dates |
Results First Posted: | October 26, 2012 |
Last Update Posted: | December 21, 2017 |
Last Verified: | November 2017 |
Keywords provided by Pascoe Pharmazeutische Praeparate GmbH:
Herpes Shingles virus disease vitamin C |
ascorbic acid antioxidant oxidative stress |
Additional relevant MeSH terms:
Herpes Zoster Virus Diseases Herpesviridae Infections DNA Virus Infections Vitamins Ascorbic Acid |
Micronutrients Growth Substances Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |